Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Apr 7 · below the Ichimoku cloud · RSI 32 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in ACXP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACXP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 5, 2025 | Scodari Joseph CDirector | Purchase at price 1.02 per share. | 24.6K | $25.00K |
| Jan 5, 2025 | Deluccia Robert JDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.02 per share. | 49.3K | $50.00K |
| Jan 5, 2025 | Luci David PChief Executive Officer | Purchase at price 1.02 per share. | 49.3K | $50.00K |
| Jan 5, 2025 | Dean Jack HDirector | Purchase at price 1.02 per share. | 9.9K | $10.00K |
| Jan 5, 2025 | Donohue James J.Director | Purchase at price 1.02 per share. | 9.9K | $10.00K |
| Jan 5, 2025 | Sailer CarlDirector | Purchase at price 1.02 per share. | 24.6K | $25.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.0 | -36.6 | 147.3 | -41.8 | -8.3 | -21.7 | -7.1 | 0.7 | -13.1 | -4.8 | −51.8% | ||
| 2025 | -10.2 | -2.9 | -45.1 | 10.3 | -9.5 | 31.4 | -36.2 | -29.1 | -7.1 | 17.0 | -22.7 | -35.8 | −84.7% |
| 2024 | -14.6 | -12.2 | -14.6 | -10.2 | 14.1 | -10.4 | -4.0 | 1.9 | -13.6 | -1.1 | -33.5 | -34.9 | −78.7% |
| 2023 | -9.5 | -8.1 | 4.5 | -13.6 | 3.7 | -14.5 | -23.4 | -4.9 | -22.3 | 256.7 | -34.2 | 8.8 | −3.8% |
| 2022 | -3.7 | -12.5 | -9.9 | 13.7 | -27.9 | 40.9 | -5.5 | -2.5 | -14.0 | 2.7 | 3.6 | 24.8 | −7.9% |
| 2021 | -11.0 | -9.0 | -0.6 | -2.7 | -4.0 | -10.0 | −32.3% |
Buy / hold / sell counts
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.